CPT code 67975 denotes the second stage of a staged, full-thickness eyelid reconstruction using a tissue flap transferred from the opposing eyelid to restore eyelid function and appearance. This reconstructive oculoplastic procedure is clinically significant nationwide because it addresses complex eyelid defects resulting from trauma, tumor resection, or congenital anomalies and often requires staged operative care and specialized surgical expertise.

Key payers in the national coverage landscape include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare and Medicare. Readers will find a concise overview of clinical context for staged eyelid reconstruction, typical sites of service (outpatient surgical centers and hospital operating rooms), and the common billing considerations tied to staged reconstructive procedures. The publication also summarizes benchmark topics and policy-relevant issues readers should expect: code intent and clinical indications, common modifiers listed in billing practice, payer coverage patterns and prior authorization tendencies, and coding pitfalls that can affect claim adjudication.

This summary is intended for billing managers, revenue cycle leaders, and clinicians involved in oculoplastic care who need a clear, national-level briefing on CPT code 67975 and the operational and policy themes that influence its use.